RxDoctor Payments DataLook up a doctor →

Murray Honick, MD

Psychiatry · Myrtle Beach, SCNPI 1932183357

Payments from drug & device makers

$125,236in general payments, 2019–2025

Across 644 payments — averaging $194.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$85K
  • Ironshore Pharmaceuticals Inc.$33K
  • AbbVie$1K
  • Sunovion Pharmaceuticals Inc.$788
  • Otsuka America Pharmaceutical, Inc.$585
  • Corium, LLC$570
  • plus $4K from 21 others

What the payments were for

  • Speaking & faculty fees$102,45082%
  • Travel & lodging$12,51810%
  • Food & beverage$10,2688%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$125,236 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.

See all psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$35,806
Medicare patients
86
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole22$42,638
CaplytaLumateperone Tosylate13$27,493
TrintellixVortioxetine Hydrobromide41$24,711
Duloxetine Hcl153$8,913
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine267$8,764
VyvanseLisdexamfetamine Dimesylate21$8,212
Lisdexamfetamine Dimesylate31$6,637
Quetiapine Fumarate58$4,444
Bupropion XlBupropion Hcl88$3,625
Aripiprazole134$3,483
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine43$3,256
Alprazolam287$3,167
Vilazodone Hcl41$2,751
Desvenlafaxine Succinate ErDesvenlafaxine Succinate32$2,560
Bupropion Hcl SrBupropion Hcl92$2,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$585$42,63822 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$490$32,92362 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$138$27,49313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 psychiatry providers in South Carolina.

Other psychiatry in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →